Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting (Q26784070)

Europe PubMed Central

14 September 2020

Europe PubMed Central

Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting

18 October 2020

copyrighted

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Antiemetics: American Society of Clinical Oncology clinical practice guideline update

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Antiemetics for Chemotherapy-Induced Nausea and Vomiting Occurring Despite Prophylactic Antiemetic Therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Aprepitant: a review of its use in the prevention of nausea and vomiting

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4573228

The current status of the use of palonosetron

28 September 2017

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Olanzapine for intractable nausea in palliative care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F595894

Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy

21 January 2018

1 reference

12 December 2020

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

12 December 2020

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

1 reference

12 December 2020

Why Do We Need Another Antiemetic? Just Ask

1 reference

12 December 2020

Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report

1 reference

12 December 2020

Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting

1 reference

12 December 2020